Histogen Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2018-02-27: Study NCT03479125; Company role Lead sponsor; Phase Observational; Status Terminated.
- 2017-06-28: Study NCT03462576; Company role Collaborator; Phase Not applicable; Status Terminated.
- 2017-06-28: Study NCT03205345; Company role Lead sponsor; Phase Phase 2; Status Unknown.
- 2016-08-28: Study NCT03439189; Company role Collaborator; Phase Not applicable; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2018-02-27 | NCT03479125 Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo | Lead sponsor | Observational | Terminated | Liver Diseases; Liver Fibrosis; Liver Cirrhosis; NASH Fibrosis; Decompensated Non-Alcoholic Steatohepatitis Cirrhosis; Orthotopic Liver Transplantation | 40 | 2019-09-30 |
| 2017-06-28 | NCT03462576 Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17 | Collaborator Lead: Meridian Bioscience, Inc. | Not applicable | Terminated Results posted | Decompensated Cirrhosis | 199 | 2019-07-15 |
| 2017-06-28 | NCT03205345 Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis | Lead sponsor | Phase 2 | Unknown | Decompensated Cirrhosis | 210 | 2019-08 |
| 2016-08-28 | NCT03439189 Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14 | Collaborator Lead: Meridian Bioscience, Inc. | Not applicable | Completed Results posted | NASH - Nonalcoholic Steatohepatitis; Cirrhosis; Portal Hypertension | 343 | 2019-05-13 |
| 2016-01-26 | NCT02686762 Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis | Lead sponsor | Phase 2 | Completed | Non-alcoholic Steatohepatitis; Fibrosis; Liver Diseases | 318 | 2019-02-28 |
| 2014-08 | NCT02230683 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension | Lead sponsor | Phase 2 | Completed Results posted | Liver Cirrhosis; Hepatic Cirrhosis; Portal Hypertension | 23 | 2015-06 |
| 2014-08 | NCT02230670 A Study of IDN-6556 in Subjects With Liver Cirrhosis | Lead sponsor | Phase 2 | Completed Results posted | Liver Cirrhosis; Hepatic Cirrhosis | 87 | 2016-01 |
| 2014-05 | NCT02138253 A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV | Lead sponsor | Phase 2 | Completed Results posted | Liver Fibrosis; Hepatic Fibrosis; Liver Cirrhosis; Hepatic Cirrhosis | 64 | 2018-03-09 |
| 2014-04 | NCT02121860 PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers | Lead sponsor | Phase 1 | Completed Results posted | Hepatic Impairment; Liver Diseases; Digestive System Diseases | 37 | 2014-07 |
| 2014-03 | NCT02077374 A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases | Lead sponsor | Phase 2 | Completed Results posted | Nonalcoholic Steatohepatitis; Non-alcoholic Fatty Liver Disease | 38 | 2015-03 |
| 2014-01 | NCT02039817 PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers | Lead sponsor | Phase 1 | Completed Results posted | Renal Impairment; Renal Insufficiency; Kidney Disease; Kidney Diseases | 16 | 2014-04 |
| 2013-09 | NCT01937130 Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF | Lead sponsor | Phase 2 | Terminated Results posted | Acute on Chronic Hepatic Failure; Acute Liver Failure; Liver Cirrhosis; Acute Alcoholic Hepatitis | 23 | 2015-02 |
| 2013-07 | NCT01912404 Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy | Lead sponsor | Phase 2 | Terminated Results posted | Alcoholic Hepatitis | 5 | 2015-08 |
| 2012-06 | NCT01653899 Caspase Inhibition in Islet Transplantation | Collaborator Lead: University of Alberta | Phase 1, Phase 2 | Completed | Diabetes | 12 | 2016-06 |
| 2011-01 | NCT01273064 Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders | Lead sponsor | Phase 2 | Terminated Results posted | Hepatitis C | 114 | 2011-10 |
| 2010-01 | NCT01051921 Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders | Lead sponsor | Phase 2 | Completed Results posted | Hepatitis C | 67 | 2011-12 |
| 2009-06 | NCT00925990 CTS-1027 in Interferon-Naive Hepatitis C Patients | Lead sponsor | Phase 2 | Completed Results posted | Hepatitis C | 70 | 2010-07 |
| 2007-12 | NCT00570336 Study of CTS-1027 in Hepatitis C Patients | Lead sponsor | Phase 2 | Completed | Chronic Hepatitis C Virus Infection | 87 | 2009-07 |
| 2004-07 | NCT00088140 A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients | Lead sponsor | Phase 2 | Completed | Hepatitis C, Chronic | 204 | 2005-10 |
| 2003-11 | NCT00080236 Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation | Lead sponsor | Phase 2 | Completed | Liver Transplantation; Hepatitis; Cholestasis; Carcinoma, Hepatocellular | 99 | 2006-01 |